about
Spontaneous trigeminal allodynia in rats: a model of primary headache.Possible sites of action of the new calcitonin gene-related peptide receptor antagonists.Possible site of action of CGRP antagonists in migraine.Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead.Calcitonin gene-related peptide (CGRP) receptors are important to maintain cerebrovascular reactivity in chronic hypertension.Sumatriptan inhibits TRPV1 channels in trigeminal neurons.Epigenetic regulation of the calcitonin gene-related peptide gene in trigeminal glia.Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage.Nociceptor sensitization in pain pathogenesisThe role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.Chemical mediators of migraine: preclinical and clinical observations.Biomarkers associated with migraine and their potential role in migraine management.Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis.CGRP antagonists and antibodies for the treatment of migraine.Morphology and neurochemistry of rabbit iris innervation.New insights of nociceptor sensitization in bone cancer pain.Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide ReceptorSumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres.The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors.Neurovascular mechanisms of migraine and cluster headache.Targeted Orexin and Hypothalamic Neuropeptides for Migraine.Serotonin, NO, and CGRP and Headache
P2860
Q30438339-DFF98F9D-A4D3-4149-A365-71A70E87C1BEQ33778781-15D5A934-F83F-46DF-AA94-BD09E19B4062Q34169056-59DB3743-9423-4EB3-82AD-42066AA386B6Q35082079-1D41EC67-BCB1-4A49-9A25-F1A57FE39326Q35362341-46F8F8A6-7019-416D-A5D2-DAB7844A038BQ35928518-50CF15B9-B454-4EF6-8D3B-A00F98B6B4CCQ36060346-288EF0A9-44F7-4F2D-B1A8-FAB065BAFDE8Q36233055-FC479852-5525-43C4-B3C1-7E5656CDF519Q37254618-94770D26-A9DA-44E5-A8FC-EF35B89ABC02Q37713262-C34DDC53-A117-4990-8564-1DDB8445594BQ37883455-07EB0852-07F7-4CE9-9184-58A5706B56E3Q38121110-BF1C7C5E-0EF7-4EBE-B0E4-BF8220D0A7EFQ38130336-4853C7E8-3204-4644-8E51-0878ACAAC90AQ38175067-7254FC37-538C-42B5-841E-FA65090CB691Q38248953-D11FB2AF-41FA-4E89-91E5-C9A8990B939BQ38258420-DBB59472-72B1-4BB3-8135-21B77C8FB6FAQ38303224-D793D87F-1553-4D1E-9F61-A846EAA80DB5Q38533414-A08FA9B7-2B86-49FB-B044-1C72EBA1BF9DQ39193269-E11D6836-4BB8-437B-827F-8876BEB94597Q39769257-5EDA2A48-65B1-4EEB-85FF-885D4EE60A0DQ42073244-306E6B55-D39C-4A65-8D4D-F434A4FF8F4EQ42732396-E99986AE-002D-46A5-B5FB-23EC055435F5Q46459487-1520A862-A880-43F3-82F4-CAA596B07FBDQ47758217-65F9E7A7-F2A2-452F-BCE9-2C3C2C1D7861Q50016389-AAE7C9FA-B223-4B9B-BC17-02EAEC6D77B2Q57986424-4CECA38C-FCFB-47BB-BF7E-17E4CE5D3D55
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CGRP receptor antagonism and migraine.
@en
CGRP receptor antagonism and migraine.
@nl
type
label
CGRP receptor antagonism and migraine.
@en
CGRP receptor antagonism and migraine.
@nl
prefLabel
CGRP receptor antagonism and migraine.
@en
CGRP receptor antagonism and migraine.
@nl
P2860
P1433
P1476
CGRP receptor antagonism and migraine.
@en
P2860
P2888
P304
P356
10.1016/J.NURT.2010.02.004
P577
2010-04-01T00:00:00Z
P5875
P6179
1031070816